Abstract
Irbesartan is an angiotensin II receptor (AT1 subtype) antagonist that has been extensively studied in the Bristol-Myers Squibb/Sanofi clinical development program. As shown in seven placebo controlled clinical trials, irbesartan provides clinically significant dose related reductions in blood pressure in patients with mild-to-moderate hypertension. Once daily dosing provides full 24 h blood pressure control with blood pressure reductions equivalent to those of twice daily dosing, and long-term control with monotherapy in a high percentage of patients. The antihypertensive effect of irbesartan is comparable to or exceeds that of leading antihypertensive agents. Whereas irbesartan demonstrates a relationship between dose and antihypertensive effect, there is no such relationship between dose and rates of adverse events or discontinuations due to adverse events, the incidence of which are comparable to those with placebo. Thus, irbesartan provides significant dose related antihypertensive effects with placebo-like tolerability.
Citations
Oct 24, 2007·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·David H G Smith
Jun 30, 2009·AAPS PharmSciTech·Rajashree S HirlekarVilasrao J Kadam
May 10, 2011·Drug Development and Industrial Pharmacy·Zhi-Liang ZhangJian-Feng Chen
Mar 14, 2009·AAPS PharmSciTech·Rajashree Hirlekar, Vilasrao Kadam
Apr 7, 2011·Chemical & Pharmaceutical Bulletin·Rikisha Jaysukhbhai BoghraSanjay Javerilal Surana
Apr 16, 2013·The Annals of Pharmacotherapy·Kathy ZaikenJudy W M Cheng
Feb 6, 2002·Drugs·Domenic A Sica
May 3, 2002·Journal of Human Hypertension·R Hernández-HernándezR Cammarata
Jan 26, 2005·Birth Defects Research. Part A, Clinical and Molecular Teratology·S AlwanJ M Friedman
Jul 27, 1999·Journal of Hypertension·W H Birkenhäger, P W de Leeuw
Apr 6, 2005·Hypertension·Timothy W R DoultonGraham A MacGregor
May 13, 1999·Clinical Therapeutics·A H GradmanW B White
Jun 11, 1999·Progress in Cardiovascular Diseases·G E SanderT D Giles
Jan 11, 2018·Organic Letters·Maria C DiPoto, Jimmy Wu